| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
Supercinnamaldehyde targets the transient receptor potential ankyrin 1 (TRPA1) channel as a potent activator. TRPA1 is a nociceptor channel expressed in sensory neurons that responds to cold temperatures, mechanical stimuli, and pain. Supercinnamaldehyde activates TRPA1 through covalent modification of cysteine residues on the channel. It is a derivative of cinnamaldehyde with enhanced potency (EC50 = 0.8 μM). The compound is used as a research tool for studying TRPA1-mediated pain pathways.
|
|---|---|
| ln Vitro |
In vitro studies demonstrate that Supercinnamaldehyde is a potent activator of the transient receptor potential ankyrin 1 (TRPA1) channel with an EC50 of 0.8 μM. It is a derivative of cinnamaldehyde that covalently binds to and activates TRPA1 by modifying its cysteine residues. TRPA1 is expressed in nociceptive neurons and is involved in pain sensation and sensory perception. The compound's potent and covalent activation mechanism makes it a valuable tool for studying TRPA1-mediated pain pathways.
|
| ln Vivo |
In vivo studies of Supercinnamaldehyde are limited in publicly available literature. As a potent TRPA1 activator, the compound has potential for in vivo investigations of pain pathways and TRPA1-mediated sensory responses. TRPA1 is involved in nociception, inflammation, and pain sensation. The compound's covalent activation mechanism may produce sustained effects. However, specific in vivo efficacy data and detailed animal model studies are not extensively reported. Further research is needed to establish its in vivo activity profile. The compound remains a research tool for TRPA1 channel biology.
|
| Enzyme Assay |
For TRPA1 channel activation assays, cells expressing TRPA1 channels (e.g., HEK293 cells or primary sensory neurons) are cultured and loaded with calcium-sensitive fluorescent dyes. Supercinnamaldehyde is dissolved in DMSO and diluted in assay buffer to varying concentrations. Cells are treated with the compound and calcium flux is measured using fluorescence plate readers. EC50 values (0.8 μM) are calculated from dose-response curves. For covalent modification assays, the compound's interaction with cysteine residues can be assessed using mass spectrometry or mutant channels. Assays are performed in replicate with appropriate vehicle controls and positive controls (e.g., allyl isothiocyanate).
|
| Cell Assay |
For in vitro cellular assays, cells expressing TRPA1 channels (e.g., HEK293 cells or primary sensory neurons) are cultured in appropriate media under standard conditions (37°C, 5% CO2). Supercinnamaldehyde is dissolved in DMSO and diluted in culture medium to desired concentrations. Cells are treated with compound for specified durations. TRPA1 channel activity is assessed by measuring intracellular calcium flux using fluorescent indicators. Cell viability and cytotoxicity can be assessed using standard assays. Each concentration is tested in replicate wells with vehicle controls and positive controls.
|
| Animal Protocol |
For in vivo animal studies of Supercinnamaldehyde, no specific published protocols are available. For general in vivo administration of TRPA1 activators, compounds are typically formulated in suitable vehicles and administered via intraperitoneal (i.p.) injection, subcutaneous (s.c.) injection, or local administration. Dosing regimens vary by study objective. For pain models, animals may be treated with compound and nociceptive responses are measured. All procedures must follow institutional animal care and use committee guidelines.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Supercinnamaldehyde are characteristic of a small-molecule TRPA1 activator. The compound has a molecular weight of 148.20, formula C9H8O2, and CAS number 70351-51-8. Purity: ≥98% (HPLC). Storage: typically at -20°C for powder; in solvent at -80°C. Solubility: soluble in DMSO and other organic solvents. Specific pharmacokinetic parameters such as half-life, clearance, and bioavailability are not extensively reported in publicly available sources. The compound is a research tool for TRPA1 studies.
|
| Toxicity/Toxicokinetics |
According to available safety information, Supercinnamaldehyde is intended for research purposes only. Standard laboratory safety precautions should be followed when handling this compound, including the use of appropriate personal protective equipment (gloves, lab coat, safety goggles). The compound should be handled in a well-ventilated area. Avoid dust formation and inhalation. In case of skin contact, wash with plenty of soap and water. In case of eye contact, rinse cautiously with water for several minutes. No clinical toxicity data are available.
|
| References | |
| Additional Infomation |
Supercinnamaldehyde is a potent activator of the TRPA1 channel with an EC50 of 0.8 μM. It is a cinnamaldehyde derivative that covalently binds to and activates TRPA1 by modifying cysteine residues. TRPA1 is expressed in nociceptive neurons and is involved in pain sensation. It has a molecular weight of 148.20 and formula C9H8O2. It is for research use only with no clinical development or regulatory approvals reported.
|
| Molecular Formula |
C12H11NO2
|
|---|---|
| Molecular Weight |
201.22
|
| Exact Mass |
201.079
|
| CAS # |
70351-51-8
|
| PubChem CID |
12480412
|
| Appearance |
Brown to reddish brown solid powder
|
| LogP |
1.7
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
15
|
| Complexity |
333
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC(=O)/C=C\1/C2=CC=CC=C2N(C1=O)C
|
| InChi Key |
CZKBLHCEDVWPRN-YFHOEESVSA-N
|
| InChi Code |
InChI=1S/C12H11NO2/c1-8(14)7-10-9-5-3-4-6-11(9)13(2)12(10)15/h3-7H,1-2H3/b10-7-
|
| Chemical Name |
(3Z)-1-methyl-3-(2-oxopropylidene)indol-2-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.9697 mL | 24.8484 mL | 49.6968 mL | |
| 5 mM | 0.9939 mL | 4.9697 mL | 9.9394 mL | |
| 10 mM | 0.4970 mL | 2.4848 mL | 4.9697 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
